16Jan/13

Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients – Forbes

Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients
Forbes
The RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which started in 2006, had randomized 2,278 patients with heart failure and anemia to receive either Aranesp or placebo. Patients in the trial started with hemoglobin levels
Amgen Announces Top-Line Results Of Phase 3 Aranesp (darbepoetin alfa PharmaLive (press release) (subscription)
Amgen’ Anemia Drug Aranesp Fails To Meet Primary Endpoint – Quick FactsRTT News
Amgen’s Aranesp for Anemia Fails to Help Heart PatientsBloomberg

all 15 news articles »

16Jan/13

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute … – PharmaLive (press release) (subscription)

Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute
PharmaLive (press release) (subscription)
Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury Research for acute and chronic kidney disease has demonstrated Bendavia’s beneficial renal effects and confirmed the significance of its novel mechanism of

and more »

15Jan/13

Publisher Milner-Fenwick Partners with the American Association of Heart … – Newswise (press release)

Publisher Milner-Fenwick Partners with the American Association of Heart
Newswise (press release)
Newswise — Hunt Valley, MD — January 15, 2013 – Milner-Fenwick, a multi-media publisher for the healthcare community, and the American Association of Heart Failure Nurses (AAHFN) announced a partnership which includes the AAHFN’s endorsement